ADVISORY/FDA Approves Cathflo Activase to Restore Function to Central Venous Access Devices as Assessed by the Ability to Withdraw Blood.Health & Medical WritersADVISORY...for WEDNESDAY NOTE TO EDITORS: Multimedia Assets Available With This Story Include Logos, Text News Releases --(BUSINESS WIRE) Genentech, Inc. (NYSE NYSE See: New York Stock Exchange :DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. ), announced that its thrombolytic agent Cathflo(TM) Activase(R) (Alteplase), a tissue plasminogen activator tissue plasminogen activator n. Abbr. TPA 1. An enzyme that catalyzes the conversion of plasminogen to plasmin, used to dissolve blood clots rapidly and selectively, especially in the treatment of heart attacks. 2. (t-PA), has been approved by the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for the restoration of function to central venous access devices (CVADs), as assessed by the ability to withdraw blood. You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?3860 This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos. If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion